Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13359107 | 0.85 | KMT2A (0.50) | USP2GLALMNAMEN1KMT2A | |
| SCHEMBL21859019 | 0.82 | TSHR (0.46) | USP2GLALMNAMEN1KMT2A | |
| SCHEMBL24037485 | 0.82 | USP2 (0.52) | USP2GLALMNAMEN1KMT2A | |
| SCHEMBL20241012 | 0.81 | KDM4E (0.55) | LMNAMEN1KMT2AKDM4EMAPT | |
| SCHEMBL21859062 | 0.81 | KDM4E (0.40) | USP2GLALMNAMEN1KMT2A | |
| SCHEMBL21859020 | 0.78 | USP2 (0.51) | USP2GLALMNAMEN1KMT2A | |
| SCHEMBL8195815 | 0.78 | USP2 (0.51) | USP2GLALMNAMEN1KMT2A | |
| SCHEMBL24037435 | 0.77 | USP2 (0.54) | USP2GLALMNAMEN1KMT2A | |
| SCHEMBL15480741 | 0.77 | USP2 (0.54) | USP2GLALMNAMEN1KMT2A | |
| SCHEMBL24037478 | 0.77 | LMNA (0.39) | USP2GLALMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210355124-A1 | Cyclic compounds as receptor modulating therapeutics and methods and uses thereof | BIONOMICS LIMITED (AU) | 2021-11-18 | — | — | US | disclosed |
| US-10954231-B2 | Anxiolytic compounds | BIONOMICS LIMITED (AU) | 2021-03-23 | — | — | US | disclosed |
| WO-2020077414-A1 | CYCLIC COMPOUNDS AS RECEPTOR MODULATING THERAPEUTICS AND METHODS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2020-04-23 | — | — | WO | disclosed |
| US-10233181-B2 | Anxiolytic compounds | BIONOMICS LIMITED (AU) | 2019-03-19 | — | — | US | disclosed |
| US-9975892-B2 | Anxiolytic compounds | BIONOMICS LIMITED (AU) | 2018-05-22 | — | — | US | disclosed |
| US-9975892-B2 | Anxiolytic compounds | BIONOMICS LIMITED (AU) | 2018-05-22 | — | — | US | disclosed |
| US-20180105524-A1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LIMITED (AU) | 2018-04-19 | — | — | US | disclosed |
| US-20180105523-A1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LIMITED (AU) | 2018-04-19 | — | — | US | disclosed |
| US-20180105524-A1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LIMITED (AU) | 2018-04-19 | — | — | US | disclosed |
| US-20180105523-A1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LIMITED (AU) | 2018-04-19 | — | — | US | disclosed |
| US-20130012508-A1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LIMITED (AU) | 2013-01-10 | — | — | US | disclosed |
| US-20130012509-A1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LIMITED (AU) | 2013-01-10 | — | — | US | disclosed |
| US-20130012509-A1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LIMITED (AU) | 2013-01-10 | — | — | US | disclosed |
| EP-2540722-A1 | Novel anxiolytic compounds | Bionomics Limited (AU) | 2013-01-02 | — | — | EP | disclosed |
| EP-2074123-B1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LTD (AU) | 2012-12-05 | — | — | EP | disclosed |
| US-8293737-B2 | Anxiolytic compounds | BIONOMICS LIMITED (AU) | 2012-10-23 | — | — | US | disclosed |
| US-8293737-B2 | Anxiolytic compounds | BIONOMICS LIMITED (AU) | 2012-10-23 | — | — | US | disclosed |
| US-20100105678-A1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LIMITED (AU) | 2010-04-29 | — | — | US | disclosed |
| US-20100105678-A1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LIMITED (AU) | 2010-04-29 | — | — | US | disclosed |
| WO-2008046135-A1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LIMITED (AU) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105523-A1 | NOVEL ANXIOLYTIC COMPOUNDS | SLC18A2, CNR1, OPRK1 | USP2 3232/4885GLA 1451/4885LMNA 4030/4885 |
| US-20210355124-A1 | Cyclic compounds as receptor modulating therapeutics and methods and uses thereof | CHRNA7, CHRNA1, CHRNA5 | USP2 3711/4885GLA 1136/4885LMNA 2733/4885 |
| US-20130012508-A1 | NOVEL ANXIOLYTIC COMPOUNDS | SLC18A2, CNR1, OPRK1 | USP2 3262/4885GLA 1480/4885LMNA 4043/4885 |
| US-10233181-B2 | Anxiolytic compounds | GABBR1, GABRA6, SLC18A2 | USP2 4010/4885GLA 695/4885LMNA 2761/4885 |
| US-20100105678-A1 | NOVEL ANXIOLYTIC COMPOUNDS | SLC18A2, CNR1, OPRK1 | USP2 3262/4885GLA 1480/4885LMNA 4043/4885 |
| US-20180105524-A1 | NOVEL ANXIOLYTIC COMPOUNDS | SLC18A2, CNR1, OPRK1 | USP2 3262/4885GLA 1480/4885LMNA 4043/4885 |
| US-20130012509-A1 | NOVEL ANXIOLYTIC COMPOUNDS | SLC18A2, CNR1, OPRK1 | USP2 3262/4885GLA 1480/4885LMNA 4043/4885 |
| US-10954231-B2 | Anxiolytic compounds | GABRA6, GABRA2, GABRA5 | USP2 3919/4885GLA 673/4885LMNA 2879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.